eJHaem (Feb 2023)
Acquired L1196M ALK mutation in anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma during alectinib administration
- Kazuhiro Noguchi,
- Yasuhiro Ikawa,
- Mika Takenaka,
- Yuta Sakai,
- Toshihiro Fujiki,
- Rie Kuroda,
- Hiroko Ikeda,
- Takatoshi Abe,
- Seisho Sakai,
- Taizo Wada
Affiliations
- Kazuhiro Noguchi
- Department of Pediatrics, School of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University Kanazawa Japan
- Yasuhiro Ikawa
- Department of Pediatrics, School of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University Kanazawa Japan
- Mika Takenaka
- Department of Pediatrics, School of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University Kanazawa Japan
- Yuta Sakai
- Department of Pediatrics, School of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University Kanazawa Japan
- Toshihiro Fujiki
- Department of Pediatrics, School of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University Kanazawa Japan
- Rie Kuroda
- Department of Pediatrics, School of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University Kanazawa Japan
- Hiroko Ikeda
- Department of Diagnostic Pathology Kanazawa University Hospital Kanazawa Japan
- Takatoshi Abe
- Department of Pediatric Surgery Kanazawa University Hospital Kanazawa Japan
- Seisho Sakai
- Department of Pediatric Surgery Kanazawa University Hospital Kanazawa Japan
- Taizo Wada
- Department of Pediatrics, School of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University Kanazawa Japan
- DOI
- https://doi.org/10.1002/jha2.646
- Journal volume & issue
-
Vol. 4,
no. 1
pp. 305 – 308
Abstract
No abstracts available.Keywords
- alectinib resistance
- ALK‐positive anaplastic large cell lymphoma
- gatekeeper mutation
- L1196M ALK mutation
- leukemic presentation
